INSIGHTS

Intelligence for
program decisions.

Analysis and perspectives from the Gauge Labs team — for emerging biotech leaders navigating high-stakes program choices.

The GLP-1 Indication Trap

Why the hottest drug class in decades has a crowding problem — and where the real opportunity lies.

Most Phase 2 failures aren't biology failures. They're patient selection failures. And by the time you know, it's too late.

By the time most emerging biotech teams see a competitor's data, they've already made the wrong call.